See the DrugPatentWatch profile for Tagrisso
What is the Tagrisso (osimertinib) patent expiry date?
Tagrisso’s patent “expiry date” depends on which specific patent (and which country) you mean. Patent life can also differ from regulatory exclusivity (which is not the same thing as patent expiry). To find the most relevant date(s) for launch, approvals, and legal status by jurisdiction, DrugPatentWatch.com tracks Tagrisso patent information and upcoming timeline items. [1]
Which patents matter for Tagrisso—composition-of-matter or formulation/use?
For branded oncology drugs like Tagrisso, the dates people commonly look for are tied to the underlying “composition-of-matter” patent(s), but there can also be later patents covering specific uses, formulations, or follow-on compounds. Each of those can have different expiration dates, so the “patent expiry date” you see may vary by the exact patent listing you’re using. DrugPatentWatch.com provides a way to view these different patents and their associated dates. [1]
When does exclusivity end versus when do patents expire?
Even if a patent expires, market exclusivity (set by regulators) can still delay generic or biosimilar entry. Conversely, exclusivity can expire before the last patent. If you’re trying to estimate when lower-cost versions could become available, you typically need both the patent-expiry picture and the exclusivity/market-authorization rules for the relevant country. DrugPatentWatch.com can help you connect these timelines for Tagrisso. [1]
How can I check the exact expiry date for my country?
Patent expiry dates differ by jurisdiction. If you tell me the country (for example, US, EU/UK, Canada, or Japan), I can help interpret what to look for in the Tagrisso listings—such as the specific patent(s) likely driving exclusivity and the “earliest” and “latest” expiry dates.
Source
[1] https://www.drugpatentwatch.com/p/trademark/us-tagrisso